CORRELATION BETWEEN HER2-LOW EXPRESSION, TUMOR-INFILTRATING LYMPHOCYTE SCORES AND CLINICOPATHOLOGIC CHARACTERISTICS, AND ITS PROGNOSTIC VALUE IN EARLY-STAGE TRIPLE-NEGATIVE BREAST CANCER AT VIETNAM NATIONAL CANCER HOSPITAL
Tóm tắt
.
Abstract
Background: HER2-low expression and TILs impacts on clinical features and prognosis in early-stage triple-negative breast cancer (TNBC) remain unclear. Our aim was to evaluate its prognostic value and correlation with clinicopathological characteristics in this population.
Method: A retrospective study of 126 patients with early-stage TNBC who did not undergo neoadjuvant systemic therapy in Vietnam National Cancer hospital from January 2018 to December 2019, HER2 expression was evaluated using the 2018 ASCO/CAP guidelines, Tumor-infiltrating lymphocyte scores (TILs) assessment were assessed based on the guide of an international TILs research group in 2014, using 40% as the cut-off.
Results: Among the 126 patients, with a median age of 54,7±11,4 years, 74,6% were HER2-0 and 25,4% were HER2-low. Compared to HER2-0 tumors, HER2-low tumors were associated with higher age (p=0,02), lower Ki67 score (p=0,05), and lower tumor-infiltrating lymphocyte (p=0,005). During a median follow-up of 54 months, the univariate analysis revealed that patients with HER2-low tumors had a worse overall survival (OS) compared to those with HER2-0 tumors (83,3% vs, 69,6%, p=0,04). However, in the multivariate analysis, HER2 expression did not show a significant association with OS. Instead, independent predictors of OS were identified as tumor-infiltrating lymphocyte scores scores (TILs) (p=0,02; HR=0,17; 95%CI 0,04-0,77) and node status (p=0,002; HR=3,8; 95%CI 1,6-9,1).
Conclusion: This study suggests that HER2-low expression are associated with a lower immune response and worse survival outcome in early-stage TNBC patients compared to HER2-0 tumors. Further investigations is needed to explore the potential of more refined classification and novel strategies that may improve the prognosis for HER2-low TNBC patients.
Từ khóa
.
Keywords
breast cancer, TILs, Her2, triple negative
Tài liệu tham khảo (References)
- Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387
- Dent R, Trudeau M, Pritchard KI, et al (2007) Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res 13:4429–4434. https://doi.org/10.1158/1078-0432.CCR-06-3045
- Cardoso F, Kyriakides S, Ohno S, et al (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol 30:1194–1220. https://doi.org/10.1093/annonc/mdz173
- Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer | New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa2203690. Accessed 27 Jul 2024
- Almstedt K, Heimes A-S, Kappenberg F, et al (2022) Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. Eur J Cancer Oxf Engl 1990 173:10–19. https://doi.org/10.1016/j.ejca.2022.06.012
- Sanomachi T, Okuma HS, Kitadai R, et al (2023) Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. Front Oncol 13:1157789. https://doi.org/10.3389/fonc.2023.1157789
- de Jong VMT, Wang Y, Ter Hoeve ND, et al (2022) Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. J Clin Oncol Off J Am Soc Clin Oncol 40:2361–2374. https://doi.org/10.1200/JCO.21.01536
- Hu X, Yang P, Chen S, et al (2023) Clinical and biological heterogeneities in triple-negative breast cancer reveals a non-negligible role of HER2-low. Breast Cancer Res 25:34. https://doi.org/10.1186/s13058-023-01639-y
- Van den Ende NS, Smid M, Timmermans A, et al (2022) HER2-low breast cancer shows a lower immune response compared to HER2-negative cases. Sci Rep 12:12974. https://doi.org/10.1038/s41598-022-16898-6
